Elevated Plasma Levels of Crosslinked Fibrinogen Gamma-chain Dimer Indicate Cancer-related Fibrin Deposition and Fibrinolysis

Summary

Cancer-related fibrin deposition and fibrinolysis were investigated by two-dimensional gel electrophoresis of human solid tumor and effusion specimen in addition to plasma samples. Fibrinogen gamma-chain dimer indicating fibrin deposition and plasmin-generated fibrinogen beta-chain fragments were identified in various solid tumor types by amino acid sequencing, mass spectrometry analysis and Western blotting. In tumor-associated effusions, these techniques allowed to observe plasmin-generated fragments of fibrinogen alpha, beta and gamma-chains in addition to elevated levels of acute-phase proteins. Similar observations were made in case of inflammation-associated effusions. No fibrin degradation product was observed in plasma samples, however, high amounts of fibrinogen gamma-chain dimer crosslinked by transglutaminase were detected in plasma from tumor patients, but not in plasma from controls and patients suffering acute infections and/or inflammations. This finding demonstrated that high transglutaminase activity may be associated with cancer. The presented data indicate that the amount of crosslinked fibrinogen gamma-chain dimer in plasma may correlate with tumor-associated fibrin deposition. The tumor-biological relevance of this potential marker protein is discussed.

Keywords

Cancer - fibrin deposition - fibrinolysis - plasma proteins - two-dimensional gel electrophoresis

• References

• 1 Nagy JA, Brown LF, Senger DR, Lanir N, Van-de-Water L, Dvorak AM, Dvorak HF. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 1989; 948: 305-26.
• 2 Nakstad B, Lyberg T. Immunohistochemical localization of coagulation, fibrinolytic and antifibrinolytic markers in adenocarcinoma of the lung. APMIS 1991; 99: 981-8.
• 3 Dvorak HF. Abnormalities of Hemostasis in Malignant Disease. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice.. Colman RW, Hirsh J, Marder VJ, Salzmann EW. eds. Philadelphia: J. B. Lippincott; 1994: 1238-54.
• 4 Semeraro N, Colucci M. Tissue factor in health and disease. Thromb Haemost 1997; 78: 759-64.
• 5 Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant pheno-type of human breast disease. Nat Med 1996; 2: 209-15.
• 6 Reich E. Activation of plasminogen: a widespread mechanism for generating localized extracellular proteolysis. In Biological Markers of Neoplasia: basic and Applied Aspects. Edited by Ruddon EW. New York: Elsevier; 1978: 491-500.
• 7 Dano K, Behrendt N, Brünner N, Ellis V, Ploug M, Pyke C. The Urokinase Receptor. Protein Structure and Role in Plasminogen Activation and Cancer Invasion. Fibrinolysis 1994; 8 (Suppl. 01) 189-203.
• 8 Vasalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067-72.
• 9 Pöllänen J, Stephens R, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991; 57: 273-328.
• 10 Dvorak RF. Thrombosis and cancer. Hum Pathol 1987; 18: 275-84.
• 11 Mitter CG, Zielinski CC. Plasma levels of D dimer: a crosslinked fibrin degradation product in female breast cancer. J Cancer Res Clin Oncol 1991; 117: 259-62.
• 12 Blackwell K, Haroon Z, Broadwater G, Berry D, Harris L, Iglehart JD, Dewhirst M, Greenberg C. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol 2000; 18: 600-8.
• 13 Bini A, Mesa Tejada R, Fenoglio Jr JJ, Kudryk B, Kaplan KL. Imunohisto-chemical characterization of fibrin(ogen)-related antigens in human tissues using monoclonal antibodies. Lab Invest 1989; 60: 814-21.
• 14 Mannucci PM. Markers of Hypercoagulability in Cancer Patients. Haemostasis 1997; 27 (Suppl. 01) 25-31.
• 15 Bottasso M, Mari D, Coppola R, Santoro N, Vaglini M, Manucci PM. Hypercoagulability and hyperfibrinolysis in patients with melanoma. Throm Res 1996; 81: 345-52.
• 16 Gotzmann J, Gerner C. 2000; A method to produce Ponceau-replicas from blots: Applications for Western analysis. Electrophoresis 21: 523-5.
• 17 Selmayr E, Mahn I, Muller-Berghaus G. Crosslinking of soluble fibrin and fibrinogen. Thromb Res 1985; 39: 467-74.
• 18 Jass JR, and Sobin LH. International Histological Classification of Tumors, WHO. New York: Springer Verlag New York, Inc.; 1989
• 19 Union Internationale Contre le Cancer.. TNM Classification of Malignant Tumors. New York: Wiley-Liss, Inc.; 1997
• 20 Gerner C, Holzmann K, Grimm R, Sauermann G. Similarity between nuclear matrix proteins of various cells revealed by an improved isolation method. J Cell Biochem 1998; 71: 363-74.
• 21 Hochstrasser DF, Harrington MG, Hochstrasser AC, Miller MJ, Merill CR. Methods for increasing the resolution of two-dimensional protein electrophoresis. Anal Biochem 1988; 173: 424-35.
• 22 Wray W, Boulikas T, Wray V, Hancock R. Silver staining of proteins in polyacrylamide gels. Anal Biochem 1981; 118: 197-203.
• 23 Sanchez JC, Appel RD, Golaz O, Pasquali C, Ravier F, Bairoch A, Hochstrasser DF. Inside SWISS-2DPAGE database. Electrophoresis 1995; 16: 1131-51.
• 24 Holzmann K, Korosec T, Gerner C, Grimm R, Sauermann G. Identification of human common nuclear-matrix proteins as heterogeneous nuclear ribonucleoproteins H and H’ by sequencing and mass spectrometry. Eur J Biochem 1997; 244: 479-86.
• 25 Fountoulakis M, Langen H. Identification of proteins by matrix-assisted laser desorption-mass spectrometry following in-gel digestion in low-salt, nonvolatile buffer and simplified peptide recovery. Anal. Biochem. 1997; 250: 153-6.
• 26 Wilkins MR, Williams KL. Cross-species identification using amino acid composition : a theoretical evaluation. J Theor Biol 1997; 186: 7-15.
• 27 Bjellqvist B, Hughes GJ, Pasquali Ch, Paquet N, Ravier F, Sanchez JCh, Frutiger S, and Hochstrasser DF. The focusing positions of polypeptides in immobilized pH gradients can be predicted from their amino acid sequences. Electrophoresis 1993; 14: 1023-31.
• 28 Gerner C, Holzmann K, Meissner M, Gotzmann J, Grimm R, Sauermann G. Reassembling proteins and chaperones in human nuclear matrix protein fractions. J Cell Biochem 1999; 74: 145-51.
• 29 Gerner C, Sauermann G. Nuclear matrix proteins specific for subtypes of human hematopoietic cells. J Cell Biochem 1999; 72: 470-82.
• 30 Francis CW, Marder VJ, Martin SE. Plasmic degradation of crosslinked fibrin. I. Structural analysis of the particulate clot and identification of new macromolecular-soluble complexes. Blood 1980; 56: 456-64.
• 31 Spraggon G, Everse SJ, Doolittle RF. Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. Nature 1997; 389: 455-62.
• 32 Dvorak HF, Nagy JA, Berse B, Brown LF, Yeo KT, Yeo TK, Dvorak AM, van de Water L, Sioussat TM, Senger DR. Vascular permeability factor, fibrin and the pathogenesis of tumor stroma formation. Ann N, Y Acad Sci 1992; 667: 101-11.
• 33 Wilhelm O, Hafter R, Henschen A, Schmitt M, Graeff H. Role of Plasmin in the Degradation of Stroma-Derived Fibrin in Human Ovarian Carcinoma. Blood 1990; 75: 1673-8.
• 34 Wildenauer DB, Körschenhausen D, Hoechtlen W, Ackenheil M, Kehl M, Lottspeich F. Analysis of cerebrospinal fluid from patients with psychiatric and neurological disorders by two-dimensional electrophoresis: Identification of disease-associated polypeptides as fibrin fragments. Electrophoresis 1991; 12: 487-92.
• 35 Felcher A, Commichau C, Cao Q, Brown MJ, Torres A, Francis CW. Disseminated intravascular coagulation and status epilepticus. Neurology 1998; 51: 629-31.
• 36 Laudano AP, Doolittle RF. Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sites, and species differences. Biochemistry 1980; 19: 1013-9.
• 37 Südhoff T, Schneider W. Fibrinolytic mechanisms in tumor growth and spreading. Clin Investig 1992; 70: 631-6.
• 38 Donati MB. Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995; 74: 278-81.
• 39 Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59: 1295-3300.
• 40 Chapman HA. Plasminogen activators, integrins and the coordinated regulation of cell adhesion and migration. Curr Op Cell Biol 1997; 9: 714-24.
• 41 Grand RJA, Turnell AS, Grabham PW. Cellular consequences of thrombin-receptor activation. Biochem J 1996; 313: 353-68.
• 42 Hoogland C, Sanchez J-C, Tonella L, Binz P-A, Bairoch A, Hochstrasser DF, Appel RD. The 1999 SWISS-2DPAGE database update. Nucleic Acids Res, 2000; 28: 286-8.